Buechner T, Hiddemann W
Department of Internal Medicine-Hematology/Oncology, University Hospital, Muenster, Federal Republic of Germany.
Blut. 1990 Feb;60(2):61-7. doi: 10.1007/BF01720509.
Chemotherapy remains the backbone of treatment in AML. Of all adult patients 65% go into remission and have a chance of longer survival and of even being cured. Among the responders, 25% can be cured by intensive and long-term chemotherapy. Since the effect of chemotherapy appears not to be limited to a special period of time, its antileukemic and curative potential could be further exploited by multiple-step chemotherapy combining double induction, intensified consolidation and long-term maintenance. Improved antimicrobial treatment and the use of hematopoietic growth factors may help making multiple-step chemotherapy practicable, thereby increasing the cure rate in AML.
化疗仍然是急性髓系白血病(AML)治疗的核心。在所有成年患者中,65%能够进入缓解期,有机会获得更长的生存期甚至被治愈。在缓解者中,25%可通过强化和长期化疗治愈。由于化疗的效果似乎并不局限于特定时间段,其抗白血病和治愈潜力可通过结合双重诱导、强化巩固和长期维持的多步骤化疗进一步挖掘。改进的抗菌治疗和造血生长因子的使用可能有助于使多步骤化疗切实可行,从而提高AML的治愈率。